PD 141479

Drug Profile

PD 141479

Latest Information Update: 24 Jan 2007

Price : $50

At a glance

  • Originator Pfizer
  • Class Anxiolytics
  • Mechanism of Action Cholecystokinin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders

Most Recent Events

  • 19 Oct 2000 No-Development-Reported for Anxiety disorders in United Kingdom (Unknown route)
  • 23 Jun 2000 Warner-Lambert has merged with Pfizer
  • 02 Feb 1996 Preclinical development for Anxiety disorders in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top